- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07570316
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease (VitaliThy)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs
The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it.
The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment.
The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment.
More information can be found here: https://clinicaltrials.argenx.com/vitalithy
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Sabine Coppieters, MD
- Telefoonnummer: 857-350-4834
- E-mail: clinicaltrials@argenx.com
Studie Locaties
-
-
-
Tbilisi, Georgië, 0114
- Werving
- New Hospitals
-
Contact:
- Lia Katcharava, MD
- Telefoonnummer: +995 599530278
- E-mail: likakatcharava@yahoo.com
-
Tbilisi, Georgië, 0102
- Werving
- LLC American Hospital Network
-
Contact:
- Nino Gabidzashvili, MD
- E-mail: endo.advice@gmail.com
-
Tbilisi, Georgië, 0119
- Werving
- LLC Todua Clinic
-
Contact:
- Tamar Khutsishvili, MD
- E-mail: Khutsishvilitamar1@outlook.com
-
Tbilisi, Georgië, 0112
- Werving
- LTD Israeli-Georgian Medical Research Clinic Healthycore
-
Contact:
- Miranda Baratashvili, MD
- E-mail: baratashvilimiranda@gmail.com
-
Tbilisi, Georgië, 0159
- Werving
- In Vitro Fertilization Center LLC
-
Contact:
- Tea Khurodze, MD
- E-mail: khurodze@yahoo.com
-
-
-
-
Tyne and Wear
-
Gateshead, Tyne and Wear, Verenigd Koninkrijk, NE9 6SX
- Werving
- Queen Elizabeth Hospital (Gateshead Health NHS Foundation Trust)
-
Contact:
- Syed Salman Razvi
- Telefoonnummer: +44 191 445 6052
- E-mail: salman.razvi@newcastle.ac.uk
-
-
-
-
California
-
Carlsbad, California, Verenigde Staten, 92012
- Werving
- Profound Research LLC at Tri-City Primary Care
-
Contact:
- Jamil Alkhaddo, MD
- Telefoonnummer: 419-681-0637
- E-mail: jamil.alkhaddo@profoundresearch.com
-
Orange, California, Verenigde Staten, 92868
- Werving
- Diabetes Associates Medical Group
-
Contact:
- Ivy-Joan Madu, MD
- Telefoonnummer: 714-202-8894
- E-mail: diabetesmd@sbcglobal.net
-
Pasadena, California, Verenigde Staten, 91101
- Werving
- Pasadena Clinical Trials
-
Contact:
- Tzu-Jen Tzao
- Telefoonnummer: 5206127860
- E-mail: ttzao@pasadenatrials.com
-
Pasadena, California, Verenigde Staten, 91105
- Werving
- Havana Research Institute LLC.
-
Contact:
- John De Beixedon, MD
- Telefoonnummer: 626-698-9794
- E-mail: drjohn@havanaresearchinstitute.com
-
San Jose, California, Verenigde Staten, 95128
- Werving
- San Jose Clinical Trials
-
Contact:
- Richard Cherlin
- Telefoonnummer: 408-358-2663
- E-mail: rcherlin@sanjosetrials.com
-
-
Florida
-
Fleming Island, Florida, Verenigde Staten, 32003
- Werving
- Northeast Florida Endocrine & Diabetes Associates (NEFEDA) - Orange Park Location
-
Contact:
- Senan Sultan, MD
- Telefoonnummer: 478-319-7900
- E-mail: drsultan@nerifl.com
-
Fort Lauderdale, Florida, Verenigde Staten, 33312
- Werving
- The Center for Diabetes and Endocrine Care
-
Contact:
- Sam Lerman, MD
- Telefoonnummer: 954-963-7100
- E-mail: slerman@diabetes-endocare.com
-
Jacksonville, Florida, Verenigde Staten, 32256
- Werving
- University of Florida Jacksonville College of Medicine
-
Contact:
- Christian Koch
- Telefoonnummer: +1 857-350-4834
- E-mail: Christian.Koch@jax.ufl.edu
-
Kissimmee, Florida, Verenigde Staten, 34744
- Werving
- Ilumina Medical Research LLC
-
Contact:
- Max Sosa-Pagan, MD
- Telefoonnummer: 857-350-4834
- E-mail: MSosapaganMD@gmail.com
-
Miami, Florida, Verenigde Staten, 33144
- Werving
- Oceane 7 Medical & Research Center, Inc
-
Contact:
- Orlando Fernandez
- Telefoonnummer: 305 261 2738
- E-mail: o.fernandez.oceane7@gmail.com
-
-
Kansas
-
Lenexa, Kansas, Verenigde Staten, 66219
- Werving
- Johnson County Clin-Trials, Inc.
-
Contact:
- Thomas Kreamer, MD
- Telefoonnummer: 913-825-4400
- E-mail: tkreamer@jcct.com
-
Wichita, Kansas, Verenigde Staten, 67226
- Werving
- Alliance for Multispecialty Research, LLC
-
Contact:
- Terry Klein
- Telefoonnummer: 316-689-6629
- E-mail: terry.klein@amr-clinical.com
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- Werving
- University of Michigan
-
Contact:
- Tae-Hwa Chun
- Telefoonnummer: 734-615-5420
- E-mail: taehwa@med.umich.edu
-
Dearborn, Michigan, Verenigde Staten, 48126
- Werving
- Metro Detroit Endocrinology Center
-
Contact:
- Ayman Elkadry, MD
- Telefoonnummer: 313-203-5300
- E-mail: aymankad73@gmail.com
-
Farmington Hills, Michigan, Verenigde Staten, 48334
- Werving
- Profound Research
-
Contact:
- Gary Edelson, MD
- Telefoonnummer: 947-254-1920
- E-mail: gary.edelson@profoundresearch.io
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64108
- Werving
- Truman Medical Center
-
Contact:
- Rajib Bhattacharya, MD
- Telefoonnummer: +1 857-350-4834
- E-mail: rajib.bhattacharya@uhkc.org
-
-
New York
-
Albany, New York, Verenigde Staten, 12203
- Werving
- Albany Medical College Community Endocrinology
-
Contact:
- Robert Busch
- Telefoonnummer: 518 489 4704
- E-mail: thyroiddoc@aol.com
-
New York, New York, Verenigde Staten, 10016
- Werving
- Endocrine Associates of West Village PC
-
Contact:
- Anastasios Manessis, MD
- Telefoonnummer: 646-660-9991
- E-mail: amanessis@endocrinenyc.com
-
-
North Carolina
-
Asheville, North Carolina, Verenigde Staten, 28803
- Werving
- Asheville Clinical Research
-
Contact:
- Lauren Bernstein
- Telefoonnummer: +1 857-350-4834
- E-mail: bbernstein@ashevilleclinicaltrials.com
-
Raleigh, North Carolina, Verenigde Staten, 27612
- Werving
- Wake Internal Medicine Consultants
-
Contact:
- Juman Takeddin, MD
- Telefoonnummer: 919-781-7500
- E-mail: jtakeddin@wakeinternalmedicine.com
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75231
- Werving
- Research Institute of Dallas
-
Contact:
- Heidi Shea, MD
- Telefoonnummer: 927-867-4658
- E-mail: hshea@eadallas.com
-
El Paso, Texas, Verenigde Staten, 79935
- Werving
- Frontier Medical Center - Academy of Diabetes Thyroid and Endocrine
-
Contact:
- Sergio Rovner
- Telefoonnummer: 915-633-9387
- E-mail: sergiorovner@hotmail.com
-
Houston, Texas, Verenigde Staten, 77040
- Werving
- Juno Research
-
Contact:
- Damaris Vega, MD
- Telefoonnummer: 713-779-5494
- E-mail: Dvega@jcct.com
-
Houston, Texas, Verenigde Staten, 77089
- Werving
- Clinic of Endocrinology
-
Contact:
- Amir Hassan, MD
- Telefoonnummer: 281-944-3610
- E-mail: amir@biopharmainfo.net
-
Irving, Texas, Verenigde Staten, 75039
- Werving
- Tekton Research Irving
-
Contact:
- Pablo Mora, MD
- Telefoonnummer: 972-566-7799
- E-mail: pablo.mora@tektonresearch.com
-
McAllen, Texas, Verenigde Staten, 78503
- Werving
- Biopharma Informatic, LLC
-
Contact:
- Gloria Ortiz, MD
- Telefoonnummer: 281-944-3610
- E-mail: gortiz@biopharmainfo.net
-
McKinney, Texas, Verenigde Staten, 75069
- Werving
- Tekton Research - McKinney
-
Contact:
- Muhammad Siddiqui, MD
- Telefoonnummer: 972-777-6011
- E-mail: muhammad.siddiqui@tektonresearch.com
-
Mesquite, Texas, Verenigde Staten, 75149
- Werving
- Southern Endocrinology Associates PA
-
Contact:
- Sumana Gangi, MD
- Telefoonnummer: 214-909-8904
- E-mail: sumana_gangi@yahoo.com
-
Shavano Park, Texas, Verenigde Staten, 78231
- Werving
- Consano Clinical Research
-
Contact:
- Daniel Katselnik, MD
- Telefoonnummer: 210-545-4900
- E-mail: katselnik.md@consanosa.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF.
- Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels >=ULN (upper limit of normal) at screening.
- Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) <0.1 mIU/L at screening.
- Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening.
Exclusion Criteria:
- History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter).
- History of RAI (radioactive iodine) therapy or received a total thyroidectomy.
- T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received <6 weeks before screening.
- Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications.
- Graves' orbitopathy/Thyroid Eye Disease (GO/TED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and/or planned corrective surgery/irradiation or medical therapy during the study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Part A - efgartigimod PH20 SC PFS
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period. |
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS) |
|
Placebo-vergelijker: Part A - placebo PH20 SC PFS
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period. |
Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS) |
|
Experimenteel: Part B - efgartigimod PH20 SC PFS
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period. |
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS) |
|
Experimenteel: Part B - placebo PH20 SC PFS
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period. |
Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS) |
|
Experimenteel: Part C - efgartigimod PH20 SC PFS
Participants will receive efgartigimod PH20 SC PFS in the part C open-label treatment period |
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS) |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A
Tijdsspanne: Up to 24 weeks (part A)
|
Free triiodothyronine: [fT3]; free thyroxine: [fT4]; ATDs: antithyroid drugs |
Up to 24 weeks (part A)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time to becoming euthyroid
Tijdsspanne: Up to 24 weeks (part A) + up to 135 weeks
|
Up to 24 weeks (part A) + up to 135 weeks
|
|
|
Efgartigimod serum concentrations over time
Tijdsspanne: Up to 24 weeks (part A) + 72 weeks (part C)
|
Up to 24 weeks (part A) + 72 weeks (part C)
|
|
|
Time to becoming euthyroid off ATDs in part A
Tijdsspanne: Up to 24 weeks (part A)
|
ATDs: antithyroid drugs |
Up to 24 weeks (part A)
|
|
Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day at week 24 in part A
Tijdsspanne: Up to 24 weeks (part A)
|
MMI: methimazole (also known as thiamazole); CBZ: carbimazole. |
Up to 24 weeks (part A)
|
|
Percentage of participants with fT3 and fT4 levels below the ULN off ATDs at week 24 in part A
Tijdsspanne: Up to 24 weeks (part A)
|
ULN : upper limit of normal; ATDs: antithyroid drugs. |
Up to 24 weeks (part A)
|
|
Percentage of participants who are euthyroid off ATDs and TRAb seronegative at week 24 in part A
Tijdsspanne: Up to 24 weeks (part A)
|
TRAb: anti-TSHR autoantibodies; ATDs: antithyroid drugs. |
Up to 24 weeks (part A)
|
|
Time to becoming euthyroid off ATDs and TRAb seronegative
Tijdsspanne: Up to 24 weeks (part A) + up to 135 weeks
|
ATDs: antithyroid drugs; TRAb: anti-TSHR autoantibodies. |
Up to 24 weeks (part A) + up to 135 weeks
|
|
Time to becoming euthyroid and receiving an ATD dose of MMI ≤5 mg/day or CBZ ≤7.5 mg/day (part A)
Tijdsspanne: Up to 24 weeks (Part A)
|
ATDs: antithyroid drugs; MMI: methimazole (also known as thiamazole); CBZ: carbimazole. |
Up to 24 weeks (Part A)
|
|
Time to having TSH within normal ranges among participants who have TSH lower than the LLN at baseline (part A)
Tijdsspanne: Up to 24 weeks (part A)
|
TSH: thyroid-stimulating hormone; LLN: lower limit of normal. |
Up to 24 weeks (part A)
|
|
Percentage of participants who remain euthyroid without ATDs
Tijdsspanne: Up to 74 weeks (part B)
|
ATDs: antithyroid drug |
Up to 74 weeks (part B)
|
|
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS for 6, 12, and 18 months
Tijdsspanne: Up to 74 weeks (part B) + up to 135 weeks
|
ATDs: antithyroid drug |
Up to 74 weeks (part B) + up to 135 weeks
|
|
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS
Tijdsspanne: Up to 72 weeks (part C)
|
ATDs: antithyroid drug |
Up to 72 weeks (part C)
|
|
Incidence of AEs and SAEs
Tijdsspanne: Up to 135 weeks
|
AEs: adverse events ; SAEs: serious adverse events. |
Up to 135 weeks
|
|
Change in ThyPRO-39 over time
Tijdsspanne: Up to 135 weeks
|
The Thyroid-Specific Patient-Reported Outcome Short Form (ThyPRO-39) 39 item version of the ThyPRO. Each item is related to a specific aspect of the participant's experience with their thyroid condition. Each item is scored on a 5-point Likert scale, and the scores are then transformed to a 0-to-100 scale. Higher scores indicate worse health status. |
Up to 135 weeks
|
|
Change in PROMIS-PF10a over time
Tijdsspanne: Up to 135 weeks
|
The Patient-Reported Outcomes Measurement Information System Physical Function-10 item (PROMIS-PF10a) is a self-administered physical functioning assessment comprising 10 items that measure respondents' ability to perform common physical tasks. Scoring involves summing the numerical responses to each item; higher scores indicate better physical function. |
Up to 135 weeks
|
|
Percentage change from baseline in total IgG levels in serum over time
Tijdsspanne: Up to 98 weeks
|
IgG: immunoglobulin G |
Up to 98 weeks
|
|
Percentage change from baseline in TRAb serum levels over time
Tijdsspanne: Up to 135 weeks
|
TRAb: anti-TSHR autoantibodies. |
Up to 135 weeks
|
|
Incidence of ADA against efgartigimod in serum
Tijdsspanne: Up to 24 weeks (part A) + up to 135 weeks
|
ADA: antidrug antibody(ies) |
Up to 24 weeks (part A) + up to 135 weeks
|
|
Incidence of antibodies against rHuPH20 in plasma
Tijdsspanne: Up to 24 weeks (part A) + Up to 135 weeks
|
rHuPH20: recombinant human hyaluronidase PH20 |
Up to 24 weeks (part A) + Up to 135 weeks
|
|
Incidence of NAb against efgartigimod in serum and rHuPH20 in plasma
Tijdsspanne: Up to 24 weeks (part A) + up to 135 weeks
|
NAb: neutralizing antibody(ies); rHuPH20: recombinant human hyaluronidase PH20. |
Up to 24 weeks (part A) + up to 135 weeks
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- ARGX-113-25-GRD-3002
- 2025-524223-42-00 (Ctis)
- 2025 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .